WEST

Help | Logout | Interrupt

Main Menu | Search Form | Posting Counts | Show S Numbers | Edit S Numbers | Preferences

Search Results -

Terms	Documents
l13 and (quil or quila or quil-a)	3

Database:
- US Patents Full-Text Database
- US Pre-Grant Publication Full-Text Database
- JPO Abstracts Database
- EPO Abstracts Database
- Derwent World Patents Index
- IBM Technical Disclosure Bulletins

Refine Search: `l13 and (quil or quila or quil-a)` Clear

Search History

Today's Date: 12/6/2001

DB Name	Query	Hit Count	Set Name
USPT	bvh$	98	L1
USPT	l1 and streptoc$	0	L2
USPT	bvh-3	0	L3
USPT	streptococ$.ti,ab,clm.	1370	L4
USPT	l4 and (peptide or polypeptide or poly-peptide or protein)	1049	L5
USPT	l5 and vaccin$	428	L6
USPT	l5 and vaccin$.clm.	106	L7
USPT	(l6 or l7) and pneumon$	280	L8
USPT	(l6 or l7) and pneumon$.clm.	154	L9
USPT	l9 and (peptide or polypeptide or poly-peptide or protein).clm.	108	L10
USPT	l10 and l1	0	L11
USPT	l1 and pneumon$	0	L12
USPT	l7 and l10	29	L13
USPT	l13 and (quil or quila or quil-a)	3	L14

WEST

Search Results - Record(s) 1 through 3 of 3 returned.

L15: Entry 1 of 3 File: USPT Jul 17, 2001

US-PAT-NO: 6262029
DOCUMENT-IDENTIFIER: US 6262029 B1

TITLE: Chemically modified saponins and the use thereof as adjuvants
DATE-ISSUED: July 17, 2001

US-CL-CURRENT: 514/26; 424/184.1, 424/204.1, 424/234.1, 514/23, 536/18.6, 536/5

INT-CL: [7] A61K 31/70, A61K 39/00, C07H 15/24

L15: Entry 2 of 3 File: USPT Jun 27, 2000

US-PAT-NO: 6080725
DOCUMENT-IDENTIFIER: US 6080725 A

TITLE: Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
DATE-ISSUED: June 27, 2000

US-CL-CURRENT: 514/26; 424/184.1, 514/25, 536/4.1, 536/5

INT-CL: [7] A61K 31/705, A61K 39/00

L15: Entry 3 of 3 File: USPT Aug 29, 1995

US-PAT-NO: 5445817
DOCUMENT-IDENTIFIER: US 5445817 A

TITLE: Pertussis toxin used as a carrier protein with non-charged saccharides in conjugate vaccines
DATE-ISSUED: August 29, 1995

US-CL-CURRENT: 424/194.1; 424/197.11, 424/240.1, 424/244.1, 424/831, 530/402, 530/403

INT-CL: [6] A61K 39/385, A61K 39/09, A61K 39/10

```
STEM:HOME
Cost is in DialUnits
Menu System II: D2 version 1.7.8 term=ASCII
                    *** DIALOG HOMEBASE(SM) Main Menu ***

 Information:
  1.  Announcements (new files, reloads, etc.)
  2.  Database, Rates, & Command Descriptions
  3.  Help in Choosing Databases for Your Topic
  4.  Customer Services (telephone assistance, training, seminars, etc.)
  5.  Product Descriptions

 Connections:
  6.  DIALOG(R) Document Delivery
  7.  Data Star(R)
```



```
      /H = Help            /L = Logoff          /NOMENU = Command Mode


Enter an option number to view information or to connect to an online
 service.  Enter a BEGIN command plus a file number to search a database
(e.g., B1 for ERIC).
?b 155

       06dec01 12:59:44 User228206 Session D1636.1
            $0.00    0.206 DialUnits FileHomeBase
     $0.00  Estimated cost FileHomeBase
     $0.00  Estimated cost this search
     $0.00  Estimated total session cost   0.206 DialUnits


File 155:MEDLINE(R)  1966-2001/Dec W5

      Set  Items  Description
      ---  -----  -----------
?s streptoc? and vaccin? and (saponin? or quil? or quila?)
           58652  STREPTOC?
          111855  VACCIN?
            5393  SAPONIN?
             691  QUIL?
              13  QUILA?
      S1       4  STREPTOC? AND VACCIN? AND (SAPONIN? OR QUIL? OR QUILA?)
?t s1/9/all

 1/9/1
DIALOG(R)File 155:MEDLINE(R)

11135505   21082588   PMID: 11214671
  Antibody response in sheep following immunization with Streptococcus
 bovis in different adjuvants.
  Shu Q; Bir SH; Gill HS; Duan E; Xu Y; Hiliard; Rowe JB
  Division of Animal Science, University of New England, Armidale, NSW,
Australia. Q.Shu@massey.ac.nz
  Veterinary research communications (Netherlands)  Jan 2001,  25  (1)
 p43-54,  ISSN 0165-7380  Journal Code: XCD
  Languages: ENGLISH
  Document type: Journal Article
  Record type: Completed
  Subfile:  INDEX MEDICUS
  Recent studies have shown that immunization with Streptococcus bovis
using Freund's complete adjuvant (FCA) may confer protection against lactic
acidosis in sheep. The major objective of this study was to compare the
antibody responses to S. bovis in a practically acceptable adjuvant
(Freund's incomplete adjuvant (FIA); QuilA ; dextran sulphate (Dex);
Imject Alum; or Gerbu) and in FCA. Thirty-five sheep were randomly
```

allocated to 7 treatment groups. Six groups were immunized with S. bovis in an adjuvant; the other group served as the non-immunization control. The primary immunization was administered intramuscularly on day 0. followed by a booster injection on day 28. Immunization with FCA induced the highest saliva and serum antibody responses. The saliva antibody concentrations in the FIA and **QuilA** groups were significantly higher than those in the Alum, Dex and Gerbu groups ($p < 0.01$). The serum antibody concentration in the FIA group was significantly higher than those in the **QuilA** , Alum. Dex and Gerbu groups ($p < 0.01$). Immunization enhanced the antibody level in faeces ($p < 0.05$), but there was no significant difference between the different adjuvant groups ($p > 0.05$). Seven and 14 days following booster immunization, the saliva antibody levels induced by **QuilA** and/or FIA were comparable with the level stimulated by FCA ($p > 0.05$). There was a strongly positive correlation ($R2 = 0.770$, $p < 0.01$) between the antibody concentrations in salival and serum. Compared with the controls, a higher faecal dry matter content was observed in the animals immunized with either FCA or **QuilA** . The change in faecal dry matter content was positively associated with the faecal antibody concentration ($R2 = 0.441$, $p < 0.05$). These results indicate that FIA and **QuilA** were effective at inducing high levels of antibody responses to S. bovis, and suggest that either Freund's incomplete adjuvant or **QuilA** may be useful for preparing a practically acceptable **vaccine** against lactic acidosis.

Tags: Animal; Comparative Study; Male

Descriptors: Adjuvants, Immunologic--administration and dosage--AD; *Antibodies, Bacterial--biosynthesis--BI; *Bacterial **Vaccines** --immunology --IM; *Sheep--immunology--IM; * **Streptococcus** bovis--immunology--IM; * **Vaccination** --veterinary--VE; Alum Compounds--administration and dosage --AD; Antibodies, Bacterial--analysis--AN; Antibodies, Bacterial--blood --BL; Bacterial **Vaccines** --administration and dosage--AD; Dextrans --administration and dosage--AD; Enzyme-Linked Immunosorbent Assay --veterinary--VE; Feces--chemistry--CH; Freund's Adjuvant--administration and dosage--AD; Injections, Intramuscular--veterinary--VE; Random Allocation; Saliva--immunology--IM; **Saponins** --administration and dosage --AD; **Streptococcus** bovis--physiology--PH; **Vaccination** --methods--MT

CAS Registry No.: 0 (Adjuvants, Immunologic); 0 (Alum Compounds); 0 (Antibodies, Bacterial); 0 (Bacterial Vaccines); 0 (Saponins); 10043-01-3 (aluminum sulfate); 66594-14-7 (Quil A); 9004-54-0 (Dextrans); 9007-81-2 (Freund's Adjuvant)

Record Date Created: 20010214

1/9/2

DIALOG(R)File 155:MEDLINE(R)

10835903 20352794 PMID: 10895910

Effects of various adjuvants on efficacy of a vaccine **against** Streptococcus **bovis and Lactobacillus spp in cattle.**

Shu Q; Hillard MA; Bindon BM; Duan E; Xu Y; Bird SH; Rowe JB; Oddy VH; Gill HS

Department of Animal Science and the Cooperative Research Centre for Cattle and Beef Industry, University of New England, Armidale, NSW, Australia.

American journal of veterinary research (UNITED STATES) Jul 2000, 61 (7) p839-43, ISSN 0002-9645 Journal Code: 40C

Languages: ENGLISH

Document type: Journal Article

Record type: Completed

Subfile: INDEX MEDICUS

OBJECTIVE: To determine efficacy of **vaccines** incorporating **QuilA** , alum, dextran combined with mineral oil, or Freund adjuvant for immunization of feedlot cattle against **Streptococcus** bovis and Lactobacillus spp. ANIMALS: 24 steers housed under feedlot conditions. PROCEDURE: Steers were randomly assigned to 4 experimental groups and a control group. Animals in experimental groups were inoculated on days 0 and 26 with **vaccines** containing Freund adjuvant (FCA), **QuilA** , dextran combined with mineral oil (Dex), or alum as adjuvant. Serum anti-S bovis and anti-Lactobacillus IgG concentrations were measured, along with fecal

pH, ruminal fluid pH, and number of S bovis and Lactobacillus spp in ruminal fluid. RESULTS: Throughout the study, serum anti-S bovis and anti-Lactobacillus IgG concentrations for animals in the Dex, **QuilA** , and alum groups were similar to or significantly higher than concentrations for animals in the FCA group. Serum anti-S bovis and anti-Lactobacillus IgG concentrations were significantly increased on days 26 through 75 in all 4 experimental groups, and there was a linear relationship between anti-S bovis and anti-Lactobacillus IgG concentrations. For animals in the **QuilA** and Dex groups, mean pH of feces throughout the period of experiment were significantly higher and numbers of S bovis and Lactobacillus spp in ruminal fluid on day 47 were significantly lower than values for control cattle. CONCLUSIONS AND CLINICAL RELEVANCE: Results suggest that immunization of feedlot steers against S bovis and Lactobacillus spp with **vaccines** incorporating Freund adjuvant, **QuilA** , dextran, or alum as an adjuvant effectively induced high, long-lasting serum anti-S bovis and anti-Lactobacillus IgG concentrations. Of the adjuvants tested, dextran may be the most effective.

Tags: Animal; Comparative Study; Male

Descriptors: Adjuvants, Immunologic--standards--ST; *Bacterial **Vaccines** --standards--ST; *Cattle Diseases--immunology--IM; *Lactobacillus --immunology--IM; * **Streptococcal** Infections--veterinary--VE; * **Streptococcus** bovis--immunology--IM; Adjuvants, Immunologic --administration and dosage--AD; Alum Compounds--administration and dosage --AD; Alum Compounds--standards--ST; Analysis of Variance; Antibodies, Bacterial--biosynthesis--BI; Antibodies, Bacterial--blood--BL; Anticoagula nts--administration and dosage--AD; Anticoagulants--standards--ST; Bacterial **Vaccines** --administration and dosage--AD; Bacterial **Vaccines** --immunology--IM; Body Weight; Cattle; Cattle Diseases--microbiology--MI; Cattle Diseases--prevention and control--PC; Dextrans--administration and dosage--AD; Dextrans--standards--ST; Feces--microbiology--MI; Freund's Adjuvant--administration and dosage--AD; Freund's Adjuvant--standards--ST; Hydrogen-Ion Concentration; IgG--biosynthesis--BI; IgG--blood--BL; Linear Models; Random Allocation; Rumen--microbiology--MI; **Saponins** --administration and dosage--AD; **Saponins** --standards--ST; **Streptococcal** Infections--blood--BL; **Streptococcal** Infections--immunology--IM; **Streptococcal** Infections--prevention and control--PC; **Streptococcal** **Vaccines** --administration and dosage--AD; **Streptococcal** **Vaccines** --immunology--IM; **Streptococcal** **Vaccines** --standards--ST; **Vaccination** --veterinary--VE

CAS Registry No.: 0 (Adjuvants, Immunologic); 0 (Alum Compounds); 0 (Antibodies, Bacterial); 0 (Anticoagulants); 0 (Bacterial Vaccines); 0 (IgG); 0 (Saponins); 0 (Streptococcal Vaccines); 10043-01-3 (aluminum sulfate); 66594-14-7 (Quil A); 9004-54-0 (Dextrans); 9007-81-2 (Freund's Adjuvant)

Record Date Created: 20001103

1/9/3

DIALOG(R)File 155:MEDLINE(R)

08565273 95348563 PMID: 7622906

Anti-polysaccharide immunoglobulin isotype levels and opsonic activity of antisera: relationships with protection against Streptococcus **pneumoniae infection in mice.**

Alonso De Velasco E; Dekker BA; Verheul AF; Feldman RG; Verhoef J; Snippe H

Eijkman-Winkler Institute for Medical and Clinical Microbiology, Utrecht University, Netherlands.

Journal of infectious diseases (UNITED STATES) Aug 1995, 172 (2) p562-5, ISSN 0022-1899 Journal Code: IH3

Languages: ENGLISH

Document type: Journal Article

Record type: Completed

Subfile: AIM; INDEX MEDICUS

Relationships between in vitro parameters (opsonic activity and anti-pneumococcal polysaccharide [PS] antibody subclasses) and in vivo mouse protection were established by logistic regression analysis. Data

were from 158 mice challenged with pneumococci after **vaccination** with synthetic oligosaccharide- and PS-protein conjugates in combination with the adjuvant **Quil** A. The hypothesis that serum opsonic activity has predictive value for protection against pneumococcal infection was tested. Serum opsonic activity was well correlated with protection (chi 2 = 35.5, P < 0.001), although a stronger correlation was observed for anti-PS IgM and IgG. The combined use of IgG and opsonic activity as predictor variables yielded the best fitting model for predicting protection (chi 2 = 74.1, P < 0.001). When opsonic activity data were added to models that included various antibody isotypes, the statistical significance of the models was enhanced. Thus, the opsonic activity of antisera induced by pneumococcal **vaccines** can predict mouse protection.

Tags: Animal; Female

Descriptors: Antibodies, Bacterial--blood--BL; *Immunoglobulin Isotypes --blood--BL; * **Streptococcus** pneumoniae--immunology--IM; Adjuvants, Immunologic; Antigens, Bacterial--immunology--IM; Bacterial **Vaccines** --immunology--IM; Mice; Mice, Inbred BALB C; Opsonins--blood--BL; Pneumococcal Infections--immunology--IM; Pneumococcal Infections --microbiology--MI; Pneumococcal Infections--mortality--MO; Polysaccharide s, Bacterial--immunology--IM

CAS Registry No.: 0 (Adjuvants, Immunologic); 0 (Antibodies, Bacterial); 0 (Antigens, Bacterial); 0 (Bacterial Vaccines); 0 (Immunoglobulin Isotypes); 0 (Opsonins); 0 (Polysaccharides, Bacterial) ; 0 (pneumococcal polysaccharide type 17F)

Record Date Created: 19950830

1/9/4

DIALOG(R)File 155:MEDLINE(R)

08359028 95193317 PMID: 7887020

Adjuvant Quil **A improves protection in mice and enhances opsonic capacity of antisera induced by pneumococcal polysaccharide conjugate** vaccines.

DeVelasco EA; Dekker HA; Antal P; Jalink KP; van Strijp JA; Verheul AF; Verhoef J; Snippe H

Eijkman-Winkler Institute of Medical Microbiology, Utrecht University, The Netherlands.

Vaccine (ENGLAND) Nov 1994, 12 (15) p1419-22, ISSN 0264-410X Journal Code: X6O

Languages: ENGLISH

Document type: Journal Article

Record type: Completed

Subfile: INDEX MEDICUS

The adjuvant effect of **Quil** A on the primary antibody response of mice to pneumococcal capsular polysaccharide conjugates was examined. **Quil** A increased the anti-capsular polysaccharide antibody titres, the protection against **Streptococcus** pneumoniae, and the opsonic capacity of the antibodies as measured in a newly developed in vitro phagocytosis assay, using the mouse macrophage cell line J774.

Tags: Animal

Descriptors: Adjuvants, Immunologic--pharmacology--PD; *Bacterial **Vaccines** --immunology--IM; *Opsonins--immunology--IM; * **Saponins** --pharmacology--PD; ***Streptococcus** pneumoniae--immunology--IM; Cell Line; Immune Sera--immunology--IM; Macrophages--immunology--IM; Mice; Mice, Inbred BALB C; Phagocytosis--immunology--IM; Polysaccharides--immunology --IM

CAS Registry No.: 0 (Adjuvants, Immunologic); 0 (Bacterial Vaccines); 0 (Immune Sera); 0 (Opsonins); 0 (Polysaccharides); 0 (Saponins); 66594-14-7 (Quil A)

Record Date Created: 19950413

?logoff hold

06dec01 12:59:59 User228206 Session D1636.2

$1.38 0.432 DialUnits File155

$0.80 4 Type(s) in Format 9

$0.80 4 Types

$2.18 Estimated cost File155

```
      $0.05  TYMNET
      $2.23  Estimated cost this search
      $2.23  Estimated total session cost   0.638 DialUnits


### Status: Signed Off. (1 minutes)
```

```
our SELECT statement is:
   s (pneunoni? or pneumonococ?) and vaccin? and (protein or polypeptide or
peptide? or amino) and (quila? or saponin? or quil)

          Items   File
          -----   ----

### Status: Break Sent.

?s (pneumoni? or pneumonococ?) and vaccin? and (protein or polypeptide or peptide? or a
mino) and (quila? or saponin? or quil)

Your SELECT statement is:
   s (pneumoni? or pneumonococ?) and vaccin? and (protein or polypeptide or
peptide? or amino) and (quila? or saponin? or quil)

          Items   File
          -----   ----
              3     5: Biosis Previews(R)_1969-2001/Dec W1
              1     9: Business & Industry(R)_Jul/1994-2001/Dec 05
              2    16: Gale Group PROMT(R)_1990-2001/Dec 05
              6    34: SciSearch(R) Cited Ref Sci_1990-2001/Dec W2
              1    47: Gale Group Magazine DB(TM)_1959-2001/Dec 05
              2    71: ELSEVIER BIOBASE_1994-2001/Dec W1
              5    73: EMBASE_1974-2001/Dec W1
              3    76: Life Sciences Collection_1982-2001/Nov

### Status: Break Sent.

?s (pneumoni? or pneumococ?) and vaccin? and (protein or polypeptide or peptide? or ami
no) and (quila? or saponin? or quil)

Your SELECT statement is:
   s (pneumoni? or pneumococ?) and vaccin? and (protein or polypeptide or
peptide? or amino) and (quila? or saponin? or quil)

          Items   File
          -----   ----
              3     5: Biosis Previews(R)_1969-2001/Dec W1
              2     9: Business & Industry(R)_Jul/1994-2001/Dec 05
              4    16: Gale Group PROMT(R)_1990-2001/Dec 05
              6    34: SciSearch(R) Cited Ref Sci_1990-2001/Dec W2
              2    47: Gale Group Magazine DB(TM)_1959-2001/Dec 05
              2    71: ELSEVIER BIOBASE_1994-2001/Dec W1
              5    73: EMBASE_1974-2001/Dec W1
              3    76: Life Sciences Collection_1982-2001/Nov
      Examined  50 files
              1    98: General Sci Abs/Full-Text_1984-2001/Oct
              1   129: PHIND(Archival)_1980-2001/Dec W1
              2   144: Pascal_1973-2001/Dec W1
              4   148: Gale Group Trade & Industry DB_1976-2001/Dec 05
              6   149: TGG Health&Wellness DB(SM)_1976-2001/Nov W3
              1   155: MEDLINE(R)_1966-2001/Dec W5
              1   180: Federal Register_1985-2001/Dec 05
      Examined 100 files
              1   315: ChemEng & Biotec Abs_1970-2001/Oct
      Examined 150 files
              4   340: CLAIMS(R)/US Patent_1950-01/Dec 04
             57   348: EUROPEAN PATENTS_1978-2001/NOV W04
            439   349: PCT FULLTEXT_1983-2001/UB=20011129,UT=20011122
              1   357: Derwent Biotechnology Abs_1982-2001/Jan B1
              2   390: Beilstein Online_
              6   399: CA SEARCH(R)_1967-2001/UD=13524
              9   440: Current Contents Search(R)_1990-2001/Dec W3
              1   442: AMA  Journals_1982-2001/Dec B1
              1   449: IMSWorld Company Profiles_1992-2001/Nov
              1   457: The Lancet_1986-2000/Oct W1
```

```
              1   459: Daily Essentials (Archival)_1996-2001/Nov W2
              4   484: Periodical Abs Plustext_1986-2001/Dec W1
       Examined 200 files
              2   570: Gale Group MARS(R)_1984-2001/Dec 05
              1   621: Gale Group New Prod.Annou.(R)_1985-2001/Dec 05
              2   636: Gale Group Newsletter DB(TM)_1987-2001/Dec 05
              1   649: Gale Group Newswire ASAP(TM)_2001/Dec 06
       Examined 250 files
              3   652: US Patents Fulltext_1971-1979
             32   653: US Patents Fulltext_1980-1989
            268   654: US PAT.FULL._1990-2001/Dec 04
              1   813: PR Newswire_1987-1999/Apr 30

   36 files have one or more items; file list includes 288 files.

?save temp
Temp SearchSave "TD453" stored
?rf
Your last SELECT statement was:
   S (PNEUMONI? OR PNEUMOCOC?) AND VACCIN? AND (PROTEIN OR POLYPEPTIDE OR -
PEPTIDE? OR AMINO) AND (QUILA? OR SAPONIN? OR QUIL)
Ref        Items   File
---        -----   ----
N1           439   349: PCT FULLTEXT_1983-2001/UB=20011129,UT=20011122
N2           268   654: US PAT.FULL._1990-2001/Dec 04
N3            57   348: EUROPEAN PATENTS_1978-2001/NOV W04
N4            32   653: US Patents Fulltext_1980-1989
N5             9   440: Current Contents Search(R)_1990-2001/Dec W3
N6             6    34: SciSearch(R) Cited Ref Sci_1990-2001/Dec W2
N7             6   149: TGG Health&Wellness DB(SM)_1976-2001/Nov W3
N8             6   399: CA SEARCH(R)_1967-2001/UD=13524
N9             5    73: EMBASE_1974-2001/Dec W1
N10            4    16: Gale Group PROMT(R)_1990-2001/Dec 05
   36 files have one or more items; file list includes 288 files.

       - Enter P or PAGE for more -
?p
Your last SELECT statement was:
   S (PNEUMONI? OR PNEUMOCOC?) AND VACCIN? AND (PROTEIN OR POLYPEPTIDE OR -
PEPTIDE? OR AMINO) AND (QUILA? OR SAPONIN? OR QUIL)
Ref        Items   File
---        -----   ----
N11            4   148: Gale Group Trade & Industry DB_1976-2001/Dec 05
N12            4   340: CLAIMS(R)/US Patent_1950-01/Dec 04
N13            4   484: Periodical Abs Plustext_1986-2001/Dec W1
N14            3     5: Biosis Previews(R)_1969-2001/Dec W1
N15            3    76: Life Sciences Collection_1982-2001/Nov
N16            3   652: US Patents Fulltext_1971-1979
N17            2     9: Business & Industry(R)_Jul/1994-2001/Dec 05
N18            2    47: Gale Group Magazine DB(TM)_1959-2001/Dec 05
N19            2    71: ELSEVIER BIOBASE_1994-2001/Dec W1
N20            2   144: Pascal_1973-2001/Dec W1
   36 files have one or more items; file list includes 288 files.

       - Enter P or PAGE for more -
?p
Your last SELECT statement was:
   S (PNEUMONI? OR PNEUMOCOC?) AND VACCIN? AND (PROTEIN OR POLYPEPTIDE OR -
PEPTIDE? OR AMINO) AND (QUILA? OR SAPONIN? OR QUIL)
Ref        Items   File
---        -----   ----
N21            2   390: Beilstein Online_
N22            2   570: Gale Group MARS(R)_1984-2001/Dec 05
N23            2   636: Gale Group Newsletter DB(TM)_1987-2001/Dec 05
N24            1    98: General Sci Abs/Full-Text_1984-2001/Oct
N25            1   129: PHIND(Archival)_1980-2001/Dec W1
N26            1   155: MEDLINE(R)_1966-2001/Dec W5
```

```
N27             1   180: Federal Register_1985-2001/Dec 05
N28             1   315: ChemEng & Biotec Abs_1970-2001/Oct
N29             1   357: Derwent Biotechnology Abs_1982-2001/Jan B1
N30             1   442: AMA  Journals_1982-2001/Dec B1
   36 files have one or more items; file list includes 288 files.

        - Enter P or PAGE for more -
?p
Your last SELECT statement was:
   S (PNEUMONI? OR PNEUMOCOC?) AND VACCIN? AND (PROTEIN OR POLYPEPTIDE OR -
PEPTIDE? OR AMINO) AND (QUILA? OR SAPONIN? OR QUIL)
Ref         Items   File
---         -----   ----
N31             1   449: IMSWorld Company Profiles_1992-2001/Nov
N32             1   457: The Lancet_1986-2000/Oct W1
N33             1   459: Daily Essentials (Archival)_1996-2001/Nov W2
N34             1   621: Gale Group New Prod.Annou.(R)_1985-2001/Dec 05
N35             1   649: Gale Group Newswire ASAP(TM)_2001/Dec 06
N36             1   813: PR Newswire_1987-1999/Apr 30
N37             0     2: INSPEC_1969-2001/Dec W1
N38             0     6: NTIS_1964-2001/Dec W3
N39             0     8: Ei Compendex(R)_1970-2001/Dec W1
N40             0    10: AGRICOLA_70-2001/Nov
   36 files have one or more items; file list includes 288 files.

        - Enter P or PAGE for more -
?p
Your last SELECT statement was:
   S (PNEUMONI? OR PNEUMOCOC?) AND VACCIN? AND (PROTEIN OR POLYPEPTIDE OR -
PEPTIDE? OR AMINO) AND (QUILA? OR SAPONIN? OR QUIL)
Ref         Items   File
---         -----   ----
N41             0    14: Mechanical Engineering Abs_1973-2001/Nov
N42             0    15: ABI/Inform(R)_1971-2001/Dec 06
N43             0    18: Gale Group F&S Index(R)_1988-2001/Dec 04
N44             0    19: Chem.Industry Notes_1974-2001/ISS 200148
N45             0    20: World Reporter_1997-2001/Dec 06
N46             0    25: Weldasearch_1966-2001/Apr
N47             0    28: Oceanic Abst._1964-2001/Nov
N48             0    29: Meteor.& Geoastro.Abs._1970-2001/Dec
N49             0    31: World Surface Coatings Abs_1976-2001/Dec
N50             0    32: METADEX(R)_1966-2001/Feb B1
   36 files have one or more items; file list includes 288 files.

        - Enter P or PAGE for more -
?b n2 n1 n3:n36;exs
       06dec01 13:08:13 User228206 Session D1636.4
            $9.46    7.569 DialUnits File411
     $9.46  Estimated cost File411
     $0.30  TYMNET
     $9.76  Estimated cost this search
     $9.99  Estimated total session cost   7.642 DialUnits
```

```
## Status: Break Sent.

?ds

Set     Items   Description
S1        880   (PNEUMONI? OR PNEUMOCOC?) AND VACCIN? AND (PROTEIN OR POLY-
                 PEPTIDE OR PEPTIDE? OR AMINO) AND (QUILA? OR SAPONIN? OR QUIL)
S2        844   RD (unique items)
S3        468   S2/1999:2001
S4        376   S2 NOT S3
?t s4/free/300-376
```

DIALOG Accession Number: 02002041 Supplier Number: 850105047
Biological Products; Allergenic Extracts; Implementation of Efficacy Review
Date: WEDNESDAY, JANUARY 23, 1985
Word Count: 205773

4/8/373 (Item 1 from file: 315)
421676
Aquila's QS-21 adjuvant enhances DNA vaccine **immune response.**
PUBLICATION DATE: 21 May 1997 (970521)

4/8/374 (Item 1 from file: 442)

00021899

Some Late Reports From the Front in War Against Various Sexually Transmitted Diseases (MEDICAL NEWS & PERSPECTIVES)

LINE COUNT: 00132 WORD COUNT: 01830

4/8/375 (Item 1 from file: 449)
00021083 (USE FORMAT 7 FOR FULLTEXT)
SMITHKLINE BEECHAM: R&D PROFILE : SYSTEMIC ANTI-INFECTIVE AGENTS
May 06 1998
Word Count: 3,363

4/8/376 (Item 1 from file: 459)
00015210
COMPANY PROFILE: AQUILA BIOPHARMACEUTICALS
February 27, 1998 (19980227)
?logoff hold

AGAAGCCTATTGGAATGGGAAGCAGGGATCTCGTCCTTCTTCAAGTTCTAGTTATAATGCAAATCCAGC
TCAACCAAGATTGTCAGAGAACCACAATCTGACTGTCACTCCAACTTATCATCAAAATCAAGGGGAAAA
CATTTCAAGCCTTTTACGTGAATTGTATGCTAAACCCTTATCAGAACGCCATGTGGAATCTGATGGCCT
TATTTTCGACCCAGCGCAAATCACAAGTCGAACCGCCAGAGGTGTAGCTGTCCCTCATGGTAACCATTA
CCACTTTATCCCTTATGAACAAATGTCTGAATTGGAAAAACGAATTGCTCGTATTATTCCCCTTCGTTA
TCGTTCAAACCATTGGGTACCAGATTCAAGACCAGAACAACCAAGTCCACAATCGACTCCGGAACCTAG
TCCAAGTCCGCAACCTGCACCAAATCCTCAACCAGCTCCAAGCAATCCAATTGATGAGAAATTGGTCAA
AGAAGCTGTTCGAAAAGTAGGCGATGGTTATGTCTTTGAGGAGAATGGAGTTTCTCGTTATATCCCAGC
CAAGGATCTTTCAGCAGAAACAGCAGCAGGCATTGATAGCAAACTGGCCAAGCAGGAAAGTTTATCTCA
TAAGCTAGGAGCTAAGAAAACTGACCTCCCATCTAGTGATCGAGAATTTTACAATAAGGCTTATGACTT
ACTAGCAAGAATTCACCAAGATTTACTTGATAATAAAGGTCGACAAGTTGATTTTGAGGCTTTGGATAA
CCTGTTGGAACGACTCAAGGATGTCNCAAGTGATAAAGTCAAGTTAGTGGANGATATTCTTGCCTTCTT
AGCTCCGATTCGTCATCCAGAACGTTTAGGAAAACCAAATGCGCAAATTACCTACACTGATGATGAGAT
TCAAGTAGCCAAGTTGGCAGGCAAGTACACAACAGAAGACGGTTATATCTTTGATCCTCGTGATATAAC
CAGTGATGAGGGGGATGCCTATGTAACTCCACATATGACCCATAGCCACTGGATTAAAAAAGATAGTTT
GTCTGAAGCTGAGAGAGCGGCAGCCCAGGCTTATGCTAAAGAGAAAGGTTTGACCCCTCCTTCGACAGA
CCATCAGGATTCAGGAAATACTGAGGCAAAAGGAGCAGAAGCTATCTACAACCGCGTGAAAGCAGCTAA
GAAGGTGCCACTTGATCGTATGCCTTACAATCTTCAATATACTGTAGAAGTCAAAAACGGTAGTTTAAT
CATACCTCATTATGACCATTACCATAACATCAAATTTGAGTGGTTTGACGAAGGCCTTTATGAGGCACC
TAAGGGGTATACTCTTGAGGATCTTTTGGCGACTGTCAAGTACTATGTCGAACATCCAAACGAACGTCC
GCATTCAGATAATGGTTTTGGTAACGCTAGCGACCATGTTCAAAGAAACAAAAATGGTCAAGCTGATAC
CAATCAAACGGAAAAACCAAGCGAGGAGAAACCTCAGACAGAAAAACCTGAGGAAGAAACCCCTCGAGA
AGAGAAACCGCAAAGCGAGAAACCAGAGTCTCCAAAACCAACAGAGGAACCAGAAGAATCACCAGAGGA
ATCAGAAGAACCTCAGGTCGAGACTGAAAAGGTTGAAGAAAAACTGAGAGAGGCTGAAGATTTACTTGG
AAAAATCCAGGAT

SP042 amino acid (SEQ ID NO:66)

CSYELGRHQAGQVKKESNRVSYIDGDQAGQKAENLTPDEVSKREGINAEQXVIKITDQGYVTSHGDHYH
YYNGKVPYDAIISEELLMKDPNYQLKDSDIVNEIKGGYVIKVNGKYYVYLKDAAHADNIRTKEEIKRQK
QERSHNHNSRADNAVAAARAQGRYTTDDGYIFNASDIIEDTGDAYIVPHGDHYHYIPKNELSASELAAA
EAYWNGKQGSRPSSSSSYNANPAQPRLSENHNLTVTPTYHQNQGENISSLLRELYAKPLSERHVESDGL
IFDPAQITSRTARGVAVPHGNHYHFIPYEQMSELEKRIARIIPLRYRSNHWVPDSRPEQPSPQSTPEPS
PSPQPAPNPQPAPSNPIDEKLVKEAVRKVGDGYVFEENGVSRYIPAKDLSAETAAGIDSKLAKQESLSH
KLGAKKTDLPSSDREFYNKAYDLLARIHQDLLDNKGRQVDFEALDNLLERLKDVXSDKVKLVXDILAFL
APIRHPERLGKPNAQITYTDDEIQVAKLAGKYTTEDGYIFDPRDITSDEGDAYVTPHMTHSHWIKKDSL
SEAERAAAQAYAKEKGLTPPSTDHQDSGNTEAKGAEAIYNRVKAAKKVPLDRMPYNLQYTVEVKNGSLI
IPHYDHYHNIKFEWFDEGLYEAPKGYTLEDLLATVKYYVEHPNERPHSDNGFGNASDHVQRNKNGQADT
NQTEKPSEEKPQTEKPEEETPREEKPQSEKPESPKPTEEPEESPEESEEPQVETEKVEEKLREAEDLLG
KIQD

SP043 nucleotide (SEQ ID NO:67)

TTATAAGGGTGAATTAGAAAAAGGATACCAATTTGATGGTTGGGAAATTTCTGGTTTCGAAGGTAAAAA
AGACGCTGGCTATGTTATTAATCTATCAAAAGATACCTTTATAAAACCTGTATTCAAGAAAATAGAGGA
GAAAAAGGAGGAAGAAAATAAACCTACTTTTGATGTATCGAAAAAGAAAGATAACCCACAAGTAAACCA
TAGTCAATTAAATGAAAGTCACAGAAAAGAGGATTTACAAAGAGAAGAGCATTCACAAAAATCTGATTC
AACTAAGGATGTTACAGCTACAGTTCTTGATAAAAACAATATCAGTAGTAAATCAACTACTAACAATCC
TAATAAG

SP043 amino acid (SEQ ID NO:68)

YKGELEKGYQFDGWEISGFEGKKDAGYVINLSKDTFIKPVFKKIEEKKEEENKPTFDVSKKKDNPQVNH
SQLNESHRKEDLQREEHSQKSDSTKDVTATVLDKNNISSKSTTNNPNK

SP044 nucleotide (SEQ ID NO:69)

GAATGTTCAGGCTCAAGAAAGTTCAGGAAATAAAATCCACTTTATCAATGTTCAAGAAGGTGGCAGTGA
TGCGATTATTCTTGAAAGCAATGGACATTTTGCCATGGTGGATACAGGAGAAGATTATGATTTCCCAGA
TGGAAGTGATTCTCGCTATCCATGGAGAGAAGGAATTGAAACGTCTTATAAGCATGTTCTAACAGACCG
TGTCTTTCGTCGTTTGAAGGAATTGGGTGTCCAAAAACTTGATTTTATTTTGGTGACCCATACCCACAG
TGATCATATTGGAAATGTTGATGAATTACTGTCTACCTATCCAGTTGACCGAGTCTATCTTAAGAAATA

TGTCAGAATT AACATCTCCA AACGCTGTTC TTGAATCGGT CATTCTGATA CCATTTTCTG 10200

CACAATAAAC CAATACACGA TTATAGGCTT CTGTAGATTT AACCACTATA TACAATTCAA 10260

TCATTTTAGA ACGATTTTGC AGATATTTTT TTAGTGGTTG GAACATGGAT ATCACACCCC 10320

AAACAGAAAT GGCTACTAAA AGAGCTCCCT CATAAGG 10357

(2) INFORMATION FOR SEQ ID NO: 192:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 6867 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 192:

CGGGACATTC TCAATCTTCT GTCTTTTGTT TTTCTCTTCT TTCTATGATA CAATGGAAAA 60

AATAAATTCA AAAGGAGTTT TTTTATGACT TATCCAAATC TCTTGGACCG CTTCTTAACC 120

TATGTTAAGG TCAACACGCG CTCTGATGAA CACTCTACTA CTACTCCAAG TACACAGAGT 180

CAGGTTGACT TCGCAACAAA TGTCCTAATT CCTGAAATGA AACGTGTTGG ACTGCAAAAT 240

GTTTACTATC TACCGAATGG TTTTGCTATT GGAACCTTGC CAGCCAACGA TCCGTCTTTA 300

ACACGTAAGA TTGGTTTTAT ATCGCACATG GATACTGCTG ATTTTAATGC TGAAGGAGTC 360

AATCCACAGG TAATTGAAAA CTACGATGGT GGTGTGATTG AACTAGGGAA TTCTGGTTTC 420

AAACTCGATC CAGCTGACTT CAAGAGTCTT GAAAAATATC CAGGACAAAC GCTCATCACA 480

ACAGATGGAA CAACCTTGCT AGGTGCTGAT GACAAGTCAG GAATTGCTGA AATTATGACA 540

GCCATTGAAT ATCTAACTGC TCATCCTGAA ATTAAGCACT GTGAGATTCG TGTTGGTTTT 600

GGTCCAGATG AAGAAATCGG TGTTGGTGCC AATAAATTTG ATGCAGAAGA TTTTGATGTG 660

GATTTTGCCT ACACTGTTGA TGGTGGTCCA CTAGGTGAAC TTCAGTACGA GACTTTCTCA 720

GCCGCTGGTG CTGAATTGCA TTTCCAAGGT CGTAATGTCC ACCCTGGTAC TGCCAAAGGG 780

CAGATGGTCA ATGCCCTTCA GCTAGCAATT GATTTTCATA ATCAACTTCC AGAAAATGAC 840

CGACCTGAGT TAACTGAAGG TTACCAAGGT TTTTACCATC TAATGGATGT GACAGGTAGT 900

GTTGAGGAGG CGCGTGCAAG CTACATCATT CGTGATTTTG AAAAAGATGC CTTTGAAGCG 960

CGTAAAGCAT CCATGCAATC TATCGCTGAT AAGATGAATG AAGAACTTGG GAGCGACCGT 1020

GTCACTCTCA ACTTGACAGA CCAGTACTAC AATATGAAAG AAGTCATTGA AAAAGATATG 1080

ACTCCAATTA CCATTGCTAA AGCCGTTATG GAAGATCTAG GTATCACGCC TATTATCGAA 1140

CCAATCCGGG GTGGAACAGA CGGCTCTAAG ATTTCCTTTA TGGGAATCCC AACTCCGAAT 1200

ATCTTTGCAG GTGGCGAAAA TATGCACGGA CGTTTTGAAT ACGTTAGCCT TCAGACTATG 1260

GAACGTGCAG TTGATACCAT CATTGGCATC GTAGCTTATA AAGGCTAAAA AGACGAGGTA 1320

GCTCAGCTAC TTCGCCTTTC TTTTTATTCT ACTGGTTTTT CTTGATTTCC AGTAGTTGTA 1380

GAAGATTCTG TTGTTTCATT TTCTGAAGTT GATTCAGCAG GTTTAGAATC TCTTGTATTG 1440

CTTGGTTTGT TTTCGTCGCT AGCAGTTTCA ATGTTAGATT CTGCAGTTGC GTTTGGTTGG 1500

TTCTCAGCAC TGGTGTTATC ACCATTTGCT TCAGCATTTC TTGCTGGACT TGTTTCTTCA 1560

CTTGCGCTAG CTTTTGACTG GATTTGATGA TTCAAAACTA GAATAGCTTT TGTCGATTCA 1620

AGTAAAGCTG TTTTGTCTTT ACTCTTAGCA GAAAGTTGAT CTAATAATGC ATCCACCTTA 1680

TCAAAGTCCG CATCAGATCC ATTATTACTT TCTAAATAAG AGTGAAGCGA CATGAGAATA 1740

TCGTAGAGTT TTTGATAGAG TACAAGTGTC TGAGGATCTT GCTCAGCATT TTCCTTTTCT 1800

TGTTGAAGGG CGCTAGCGAT ACGAGTCAAG ACATCTTTTA CCTGACTGTT TACTTCATCC 1860

AAGTCTGCAT CAGCCTTGTT TGTGGCAGCT TTTAGATTTT CTACTTCTTC TGCCAAGGAT 1920

TGTCTGATTC CTTCTTCATG GATTTGTTCC AAGAGTTGAT TTGCCTTGCT CAAAAGACTT 1980

TCTACTTCTT CCTTGCTATC TGTCGCAGAT TATTGGTTGC TATCTACCAT GTACTCCTAA 2040

AACAGGAGAG TTATAATCCA AGATTACAAG GCCTTACAGA AATAAGAAAT CCAGATAAGA 2100

CAATGTTCGT CCAAGACGCT ATTCGCTTCG CACAGCAGCA CGGATTCAAT ATGCTTTAAT 2160

TTTAAAGTTT AGGTGTCAAG ACCTCTTTTT AGTGTGCCCA AAATTTAGAG AAGTAATCAA 2220

TCAACTAACT TTTATTTTTT TCAAACTTTC AGTAAACTGA CCTAAAGCTA ACTCAATCTG 2280

TCTTTGTAGA TGCTTCTGCT ATCAGCTAGA AGTTGATCTA CTTTTGCCAA GACTGCCTTC 2340

TCATCAAAAG TTCCAGGTTG ATAGTTGGAT TGCAGGGATG GAATCTTGTT TTTCAAAGCC 2400

GCTTCATATC CCTTAGTTTG AACCTTGATG TAGTGATTGT GGTCGCCATG AGGAATCACA 2460

AAACCTTCTG AATCTTCACT TATAATTCGA TTGGCATCAA AACCATGACC ATCTTCTTCC 2520

TCATGATGGA CATGTAGTGA CGGATTACTT AATACAGAAC TAGAAGAACT TCCTACCTCT 2580

TCCGTGTTAG AGTGTGATGG GGGATTGTTA AGAGATGACT TAGGAATATA GTGATAGTGA 2640

TCCCCATGTC TTACTATATA AGCATCACCT GTATCTCTGA CAATATCATT AGGGTTAAAG 2700

ACATATGTGG CTGCTAATTC ACCTGCCGAC AAGTCACTCT CAGGAATGAA ATGATAGTGA 2760

CCACCATGTG GTACTATAGT AGATTGAAAT AGAATATGAG CAAATTGATA AGGGGATTTT 2820

AAAGTAATTT CTAACAATGA TTTAGAAACT ATGATGTGCT ATTCTAAATT CAACTCACTA 2880

TATATAACCA TCATCGGTAG TATAACGTCC CTGTAATTTT GCTACAGATA CTTCTGCACT 2940

AGCTCCTTTA TCGTCTTTAC CATGTTCTTG TTTTTGGCGA TTGATTTCAT CTTTTGTTCG 3000

TACATTTTCT GCATGAGCTT GATCTTTAAG GTAAACATAA TACTTTCCAT CTACCTTAAT 3060

AATATATCCT CCCTTAACCT AACTGACGAT ATCTTGATCT TTCGGCTGAT AGTTGGGGGC 3120

TTTCATTAAT AGCTCTTCAC TAAAGAGCGC ATCAAAAGGA ACTTTACCAT TATAGTAGTG 3180

ATAATGATCG CCATGAGAAG TTACATAACC TTGATCTGTA ATCTTAATAA CAATTTGTTT 3240

TGCTTGAATT CCTTCTTTTT GACTAACCTA GTCTGGAGTC AAATTTTCAG TCTTCTTAGT 3300

GTCTTTATTA CTGTTTACAT ATGAAACACG ATTTTTATCT GTATTGGCCT GTTAGCTATG 3360

TTGGTTCAGA GCATAAACAC ACAGACTTAA GGAAAGGATA ACAACAGATC CAGCTGCTAT 3420

ATATTTCTTT TTAAATTTCA TAATTACCTC ATTTCTATAA TTATTTATAT GATGTCTTCA 3480

TTATTAAATG ATTAAATAAA TTAATTAACC AATTAATTAA CTAGTAAATA TTCCACCTCT 3540

TTTTAAGTTG TATGTCAAGA AATTTTATAT ATTAATAATA AAATGAAATT CTCCCAAAGT 3600

CAGAGTTTTA TTTCTAACTT TTGAGAGAAC TTCATTTTTG ATTCAGACTT TTTCTACTGC 3660

TATTCCTTAC GCTATGAGAT CAGATAAATT CTTTTTTATC ACTTCTCCAC TTGGCAATCT 3720

TAATTCAATC GTTCCATCCA TATTGAATAT AACACTATCT AAGCCTAATC CGTAACTAGC 3780

TGTAAATTTT TCTAATTTTT CTTGTACAGG ATCTACTGCT GGAGCTTCCT CTAATGCTGG 3840

ATCTAACATA GGGTCACTCC CCACATTCCC TTCTGGATTC AACATTCCAT TATCCGTTGA 3900

GTTTTCTGGT TTTACAGGTT TTTCGTTTGG TGCCTCTGGT AAAGAATCTG CTGGTTTATT 3960

TTCTGTTGGT TGGTTCTCAA CTGTTCCAGT AGATACTTTT CCATTTTCAG ATGGTTTATT 4020

TTCACCATTT CCTTGAGGTG CTTCTCCTGT AAAATCTGCC ATATTCTTTT TAATGACTTC 4080

TCCCGATGGT AAATATAATT CAATTGTTCC GTCCATATTA AACAAGACAT TTTCTAGCTT 4140

CATCCCATAA CTTTCAGCAA ATTTTGCTAC TTTTTCTTGT ACAGGATCCA CTGTAGGAAC 4200

TTCTTCTAAC GTTGAATTAC TAGTACTATT CCCAGTTTCA GAAAGTTTTT CTTTTTCTAC 4260

CTTCTCACTA GTCTTTGGTT CTTCTACCTT TTCATCAAGT TTTAAGTTTT CTTGTGCTTT 4320

ATTCCTTTTA AATTGTGGTA GAATACTTGG TTTATCAGTT TGATTTTCTT TTTCCAAGAT 4380

AGGTACTTCC ACAATATAAG TCGATTGATT GTCCAAATAA GCATTTGCCA TGAAGGTTAC 4440

AGGAATTTTA TTTCCGGCCG TTCTGGTTGT TCCTTGGTTT AATTTCGGAA TCGGTAATTT 4500

GATTTCACCA ACTTTATAGT TATTTTCTAA ATAAGCATTT CCATGAAATT CATCAAACAC 4560

TCTGACTAAA GCATCAGTTC CTTTAGGCAC TGCAAATTGA GGGTTCACTC TTAAATAAGT 4620

ATCCCCTGCA TGGAAAGGAT AGAAAATCGT TTGACTGGCC ATTTTGTAAG CTAAAGAGGT 4680

TGGAACTGTA AATGTACCAT CATAACTTAC TTCTGGATAA TCTTTTGAAG CGATAGTATA 4740

CTTAAATGTT TGTCCTGGTA AATAAGGTTG ATCTAATTCA AAGTTTGCAA TATTCCCTAC 4800

TCCTTCTCCA AATACTTTAC CAGATACTTT CTCCAATACT TTTCCATCTG GTGTTATTAA 4860

TTTTACTAGC ATATTGATAC CTAATTTTTT CTCCAATTCA GGCGGAAAAC TAAAAGAAAC 4920

GCGTTTTTGA CCATTGGCTA GAGTAAAGTT TTGATTATTA AACGTACTAT TTTTTAACAA 4980

ATTAACAACA TTCGTTAATT CTTCTCCAGT ATAAACTTTA TTCCCTTCTT TTTTAGCAAC 5040

TCCTTCTTCG GGTTTAAACA GTTCATAGTT ACTGTGAGAA TGACCAATTC CAACCGGTTT 5100

ATGTTCATCA ATCGGATCTG CATGATGGTG ATCTCCATGC GGATAAATAA TCGCATTTTT 5160

TTCTTTATTC ACGACAATAC TTTCACGTTT GACACCATAT TGTTTCATAA TGCCAGCAAT 5220

TTTTTCTTCG ATTTTTTTAT CTAAATCTTT CATTTCTTTG GCATTACTTG GATAATCCTG 5280

TTCATGAGAT GACAAAGAAT CTAATCCATT ATGACTAGTT TTAACTTCCT CTAAATGTTT 5340

TTGCGCAsCT TAATTTGCTC TTCTGTCAAG TCCTTCTTGA AGAAATAATG ATTGTGGTCT 5400

CCGTGACTCA TGACAAAACC TGATTCATCT TCAGCGATAA TACGATTAGC ATCAAATCCG 5460

TATCCATCTT CTTCATGTTT CTCATGTGAA GTTCCTGGAT TGATTGGAAG AGATGGAGAA 5520

GGTGTTGCTA GACTATTGTT TGGAAGAGTC GGTTGCCCAA TTTGATTTGA TTTTGGAATG 5580

TAATGGAAAT GATCACCATG TCTTACAATA TAAGCTGTAG CCGTTTCTTC AACGATATCT 5640

TTTGGATTAA AAATATAACC ATCAGATGCT GAAGAGAGCT CCTTACTTGT CGTTAAAGAA 5700

GAAGGATTGC TTGAAAGACT GCCTAGACTA GACACTACTT CATTAGGTTT TGCATTTGTA 5760

GAAACTGTAG AACCAGTTCC ACTGATAGGC ACCATTCTGG CAATCTTTTC TTCTAAGGCA 5820

GAAAGCTTGC TGTAAGGAAT AAAGTGGTAA TGGTCGCCAT GCGGAATCGC AACTCCATTT 5880

GGTGTACGAC TGATAATCTT AGCAGGGTCA AAGACCAGGC CATCTGATTC ACTGTAACGT 5940

TGGGCGCTAG GTGAATCATA GAGTTCCTTC AAAAGACTCT GGAGATTTTC AGATTTATTT 6000

GCTGGCTTGC TAGTTGATCC TTTTGCTACA GATTGCGTGT TATTGTCACT AGCTGTTGAA 6060

GAATAGCTTA ACTGACTCGG TTGCATATTT TTTCCAGCCA GATGTGCTTT AGCTGCTGCT 6120

AATTCACTAG CAGATAAATC GCTTTTGGGA ATGTAGTGAT AGTGACCTCC ATGAGGAACG 6180

ATATAAGCAT TACCCGTATC TTCGATAATA TCAGCTGGAT TAAAGACATA ACCATCATTT 6240

GTCGTATATC GTCCCTGAGA CCTTGCTACA GCAACATTAG AGTTAACCTT CTCATTATCT 6300

TTGACATGTT CTTGTTTTTG ACGATTGATT TCATCTTTAG TTCGAACATT ATCAGCATGA 6360

GCTGCATCTT TCAGGTAGAC ATAATATTTT CCATCGACCT TGATGATATA ACCACCCTTG 6420

ACTTCATTGA CAATATCAGC GTCTTTAAGT TGATAGTTTG GATCCTTCAT CAAGAGTTCT 6480

TCACTAAAGA GGGCATCATA AGGAACTTTC CCATTATAGT AATGATAGTG GTCACCGTGT 6540

GACGTTACAT AGCCCTGATC TGTAATTTTG ATTACAATTT GCTCAGCCTG AATTCCTTCT 6600

TTCTGGCTAA CCTGGTCTGG TGTCAAGTTT TCACTTTTCT GACTTGACTG GCTGCCATCC 6660

ACATAAGAGA CACGATTATT GTCCTTATTT TCCTGCGAAC GATGCTGGTT TAGTGCATAG 6720

GCACATAGAC TCAAGGATAC GATAACAGCT GATCCAGCTG CTATATATTT TTTACTAAAT 6780

TTCATAAATC CCTCATTTCA ATAAATGATG AAGTTTTTTC TCAACTTCTT TTACTTTATT 6840

AAATAGTTTT CTAAACCCGG GGGTACC 6867

(2) INFORMATION FOR SEQ ID NO: 193:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 999 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 193:

CGTTCTAAAA ATGCAGTACG TTTGATTGAG AAATCAGTTA AAGGTATGCT TCCACACAAT 60

ACACTTGGAC GCGCTCAAGG TATGAAGTTG AAAGTATTTG TTGGAGCTGA GCACACTCAC 120

GCTGCACAAC AACCAGAAGT TCTTGACATT TCAGGACTTA TCTAAGGAAA GGAACAATAA 180

AGTATGTCAC AAGCACAATA TGCAGGTACT GGACGTCGTA AAAACGCTGT TGCACGCGTT 240

CGCCTTGTTC CAGGAACTGG TAAAATCACT GTTAACAAAA AAGATGTTGA AGAGTACATC 300

CCACACGCTG ACCTTCGTCT TGTCATCAAC CAACCATTCG CAGTTACTTC AACTGTAGGT 360

TCATACGACG TTTTCGTTAA CGTTATAGGT GGTGGATACG CTGGTCAATC AGGAGCTATC 420

CGTCACGGTA TCGCTCGTGC CCTTCTTCAA GTAGACCCAG ACTTCCGCGA TTCATTGAAA 480

CGCGCAGGAC TTCTTACACG TGACTCACGT AAAGTTGAAC GTAAGAAACC AGGTCTTAAG 540

AAAGCTCGTA AAGCATCACA ATTTAGTAAA CGTTAATTCG AAAGAATTAC TATACTTATA 600

CAGAGCACCT TTCGGGGTGT TCTTTTTTTA TACTTTCTTA CTAAATTGGT GCAATTGACA 660

CAGTTGTTGC GACTTTAGTC GCTTACAAAT GTGGCTGCAA CCTGACATGG TCAGTTGCCT 720

CAAAACGTTA ATCAATACGA TTATATCAAC GTTTCAAAGC ACTCAAGGGT TTACCCTATG 780

GGTGCTTTTT TCTATACTTT CTAAAAAAGT TTACCCTAAA ATTTGCCCTA AAATTACCCT 840

ACTTATTTTT AAGATGTTGG TAGGCAACTT GTCCAGCAGA TAATGGAACT ATGTTTGAAG 900

TATTAACATA AGTCTTAGTT GTAACGGTAT CGCTATGAGT TAATGCTTCA GAAATGGCTT 960

GCTGCTGGAC TAGCTGCTTC ACCATTGTTT TTAGGATAGT CAGAAATATA GCTTAATTTC 9780

CCAGTCCATT TTTTATCAGG ATACACTTTA GAAGTAAAGC TTACTTCTTG ACCTACAGAA 9840

AGGTTGGCTA GATTGTACTC AGACAATTCT CCCTTGACTT GTAAATTTTC ATTGCTGACA 9900

ATATGAACCA TAACTTGACT CGCCCCTGTT GGAGATTTAG AAACATTGCT ATTGACTTCG 9960

ACCACAGTTC CCTCTAGGGT ACTGAGAACA GTTGTTGCAT CCAATTGACT TTGAGCCTTG 10020

CTTAATTGCG CCGCAGCATC TGCACGCGCA TCACGGGCAT CACCCAATTG AGCGTCAATA 10080

GAAGCAACAG AATTTCCAGC CACTGGAGTT GGGCTTTGCA CCGTTGCATC TTCTCCTCCT 10140

ACTGGCGCTG GTAACTGTGG AGCCGGAGCT GAAGCGGCTT CATTTCGTGC TTGATTGAGT 10200

TCATTGATAT GACGATCTGC CCTAGCTACT GCTCGACTAG CTGAATCATA GGCCGCCTGC 10260

GCTTCTGAAC TACTGTACTT GACTAAAGCC TGCCCTTCGC TGACCTTATC GCCCACAGAA 10320

ACAAGGATTT CATCTAAATC ACCCTTACTA GCATCAAAAT AAACATATTG TTCATTTTTT 10380

GCTGTTACTG TCCCTGACAA TAAAACAGAG GAGGCCACGC TTCCTTCCTT GGCAACAACA 10440

AGATGAGTAG GCTCATCTTT TAGAGCAGTC TGAGAAGGTT GTCTAAAGAG TAAAATCCCC 10500

CCAGCACCCA ATACAACTAC ACTCGCAGCA CCGATTGCTG CATACAGTTG CCACTTTTTA 10560

GCTTTACCAT TCTTTTTCTT CATAATGAAA CTCCTTTTCT TTTTTACAAT ACTTTGCTAT 10620

TATACCAAAT TTCCCTCCAG CAAACAATAC AGTTCAGGAT TAAACAATCG TTCGGAATTT 10680

TGCTTTTCGG 10690

(2) INFORMATION FOR SEQ ID NO: 94:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 8195 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 94:

GAGAAAGCGC CCACGTTTCC CCGAAGGGAG AAAGGCGGAC AGGTATCCGG TAAGCGGCCA 60

GGGTCGGAAC AGGAGAGCGC AACGAGGGAG CTTCCCAGGG GGAAACGCCT GGTATCTTTA 120

TAGTCCTGTC GGGTTTCGCC ACCTCTGACT TGAGCGTCGA TTTTTGTGAT GCTCGTCAGG 180

GGGGCGGAGC CTATGGAAAA ACGCCAGCAA CGCGGCCTTT TTACGGTTCC TGGCCTTTTG 240

CTGGCCTTTT GCTCACATGT TCTTTCCTGC GTTATCCCCT GATTCTGTGG ATAACCGTAT 300

TACCGCCTTT GAGTGAGCTG ATACCGCTCG CCGCAGCCGA ACGACCGAGC GCAGCGAGTC 360

AGTGAGCGAG GAAGCGGAAG AGCGCCCAAT ACGCAAACCG CCTCTCCCCG CGCGTTGGCC 420

GATTCATTAA TGCAGCTGGC ACGACAGGTT TCCCGACTGG AAAGCGGGCA GTGAGCGCAA 480

CGCAATTAAT GTGAGTTAGC TCACTCATTA GGCACCCCAG GCTTTACACT TTATGCTTCC 540

GGCTCGTATG TTGTGTGGAA TTGTGAGCGG ATAACAATTT CACACAGGAA ACAGCTATGA 600

CaTGATTACG AATTCGAGCT CGGTACCCGG AAAATCCAGA AAATGCTTGA AAAAAATCCT 660

AGAAGATGGT ATAATACTAA ATTGTAAGGG TTATCACATA TAACTCAAAA AAAGAAAGAA 720

CAAAAGGAGA GTCAAACTAT GGCTTCTAAA GATTTCCACG TAGTGGCAGA AACAGGTATT 780

CACGCACGTC CAGCAACATT GTTGGTACAA ACTGCTAGCA AATTTGCTTC AGATATCACT 840

CTTGAGTACA AAGGTAAATC AGTTAACCTT AAATCAATTA TGGGTGTTAT GAGTCTTGGT 900

GTTGGCCAAG GTGCTGACGT AACTATCTCA GCTGAAGGTG CAGATGCAGA TGACGCTATC 960

GCTGCAATCT CAGAAACAAT GGAAAAAGAA GGATTGGCAT AAGGGAAATG ACAGAAATGC 1020

TTAAAGGAAT CGCAGCATCT GACGGTGTTG CAGTTGCAAA AGCATATCTA CTCGTTCAGC 1080

CGGATTTGTC ATTTGAGACT ATTACAGTCG AAGATACAAA CGCAGAAGAA GCTCGCCTTG 1140

ATGCCGCTCT ACAGGCATCA CAAGACGAGC TTTCTGTTAT TCGCGAGAAA GCAGTAGGTA 1200

CGCTCGGTGA AGAAGCAGCT CAAGTTTTTG ATGCTCACTT AATGGTTCTT GCTGACCCAG 1260

AAATGATCAG CCAAATCAAG GAAACTATCC GTGCGAAGAA AGTGAATGCA GAAGCAGGTC 1320

TGAAAGAAGT TACAGATATG TTTATCACTA TCTTTGAAGG CATGGAAGAC AACCCATACA 1380

TGCAAGAACG CGCAGcGGAT wTCCGCGACG TGACAAAACG TGTATTGGCA AACCTTCTTG 1440

GTAAAAAATT GCCAAACCCA GCTTCTATCA ATGAAGAAGT GATTGTGATT GCGCATGACT 1500

TGACTCCTTC AGATACAGCT CAATTGGACA AAAACTTTGT AAAAGCTTTT GTAACCAACA 1560

TTGGTGGACG TACAAGCCAC TCAGCTATCA TGGCACGTAC ACTTGAAATT GCTGCTGTAT 1620

TAGGTACAAA TAACATCACT GAAATCGTTA AAGACGGTGA CATCCTTGCT GTTAACGGGA 1680

TCACTGGAGA AGTGATTATC AACCCAACAG ATGAACAAGC GGCAGAATTT AAAGCAGCTG 1740

GTGAAGCCTA TGCGAAACAA AAAGCTGAAT GGGCACTTTT GAAAGATGCT CAAACAGTGA 1800

CTGCTGACGG TAAACACTTC GAGTTGGCTG CTAATATCGG TACTCCAAAA GACGTTGAAG 1860

GTGTTAACAA CAACGGTGCA GAAGCTGTTG GACTTTACCG TACAGAGTTC TTGTACATGG 1920

ATTCTCAAGA CTTCCCAACT GAAGATGAGC AGTATGAAGC ATACAAGGCT GTTCTTGAAG 1980

GAATGAACGG TAAACCTGTT GTCGTTCGTA CAATGGATAT CGGTGGAGAT AAGGAACTTC 2040

CTTACTTCGA TATGCCTCAC GAAATGAACC CATTCCTTGG ATTCCGTGCT CTTCGTATCT 2100

CTATCTCTGA GACTGGAGAT GCTATGTTCC GCACACAAAT CCGTGCTCTT CTTCGTGCGT 2160

CTGTTCACGG TCAATTGCGT ATCATGTTCC CAATGGTTGC GCTCTTGAAA GAATTCCGTG 2220

CAGCGAAAGC AGTCTTTGAT GAAGAAAAAG CAAACCTTCT TGCTGAAGGT GTTGCAGTTG 2280

CGGATAACAT CCAAGTTGGT ATCATGATCG AGATTCCTGC AGCGGCTATG CTTGCAGACC 2340

AATTTGCTAA AGAAGTTGAC TTCTTCTCAA TTGGTACAAA CGACTTGATC CAATATACAA 2400

TGGCAGCAGA CCGTATGAAC GAACAAGTTT CATACCTTTA CCAACCATAC AACCCATCAA 2460

TCCTACGCTT GATTAACAAT GTGATCAAAG CAGCTCACGC TGAAGGTAAA TGGGCTGGTA 2520

TGTGTGGTGA GATGGCTGGT GACCAACAAG CTGTTCCACT TCTTGTCGGA ATGGGCTTGG 2580

ATGAGTTCTC TATGTCAGCA ACATCTGTAC TTCGTACACG CAGCTTGATG AAGAAACTCG 2640

ACACAGCTAA GATGGAAGAG TACGCAAACC GTGCCCTTAC AGAATGCTCA ACAATGGAAG 2700

AAGTTCTTGA ACTTCAAAAA GAATACGTTA ATTTTGATTA ATCGAAAAGT CCCTGCAACT 2760

CAGTTACAGG GATTTTTTTG ATATTTTAAA AAGAATTTTC AAGAAAATCT TTCTTATAGA 2820

AAGTCCAACC TTGAAAAAGT AGTGGTCAGA ACAAAAAATA CTTAAATGGT TCATAAAATT 2880

CTTGACAAGT TGGATATTTA GGAGTAAACT ATTAACCAGT TAAGTAATAG AGAGGAGTTT 2940

CTGCAATTTA GAAATGAATT GCAACTAGAA ATATCAAATA GAAAGAGAGT TTCGATGAAA 3000

ATTAATAAGA AATACCTTGT TGGTTCTGCG GCACTTTGAT TTTAAGTGTT TGTTCTTACG 3060

AGTTGGGACT GTATCAAGCT AGAACGGTTA AGGAAAATAA TCGTGTTTCC TATATAGATG 3120

GAAAACAAGC GACGCAAAAA ACGGAGAATT TGACTCCTGA TGAGGTTAGC AAGCGTGAAG 3180

GAATCAATGC TGAGCAAATC GTCATCAAGA TAACAGACCA AGGCTATGTC ACTTCACATG 3240

GCGACCACTA TCATTATTAC AATGGTAAGG TTCCTTATGA CGCTATCATC AGTGAAGAAT 3300

TACTCATGAA AGATCCAAAC TATAAGCTAA AAGATGAGGA TATTGTTAAT GAGGTCAAGG 3360

GTGGATATGT TATCAAGGTA GATGGAAAAT ACTATGTTTA CCTTAAGGAT GCTGCCCACG 3420

CGGATAACGT CCGTACAAAA GAGGAAATCA ATCGACAAAA ACAAGAGCAT AGTCAACATC 3480

GTGAAGGTGG AACTCCAAGA AACGATGGTG CTGTTGCCTT GGCACGTTCG CAAGGACGCT 3540

ATACTACAGA TGATGGTTAT ATCTTTAATG CTTCTGATAT CATAGAGGAT ACTGGTGATG 3600

CTTATATCGT TCCTCATGGA GATCATTACC ATTACATTCC TAAGAATGAG TTATCAGCTA 3660

GCGAGTTGGC TGCTGCAGAA GCCTTCCTAT CTGGTCGAGG AAATCTGTCA AATTCAAGAA 3720

CCTATCGCCG ACAAAATAGC GATAACACTT CAAGAACAAA CTGGGTACCT TCTGTAAGCA 3780

ATCCAGGAAC TACAAATACT AACACAAGCA ACAACAGCAA CACTAACAGT CAAGCAAGTC 3840

AAAGTAATGA CATTGATAGT CTCTTGAAAC AGCTCTACAA ACTGCCTTTG AGTCAACGAC 3900

CTGTTCACGG TCAATTGCGT ATCATGTTCC CAATGGTTGC GCTCTTGAAA GAATTCCGTG 2220

CAGCGAAAGC AGTCTTTGAT GAAGAAAAAG CAAACCTTCT TGCTGAAGGT GTTGCAGTTG 2280

CGGATAACAT CCAAGTTGGT ATCATGATCG AGATTCCTGC AGCGGCTATG CTTGCAGACC 2340

AATTTGCTAA AGAAGTTGAC TTCTTCTCAA TTGGTACAAA CGACTTGATC CAATATACAA 2400

TGGCAGCAGA CCGTATGAAC GAACAAGTTT CATACCTTTA CCAACCATAC AACCCATCAA 2460

TCCTACGCTT GATTAACAAT GTGATCAAAG CAGCTCACGC TGAAGGTAAA TGGGCTGGTA 2520

TGTGTGGTGA GATGGCTGGT GACCAACAAG CTGTTCCACT TCTTGTCGGA ATGGGCTTGG 2580

ATGAGTTCTC TATGTCAGCA ACATCTGTAC TTCGTACACG CAGCTTGATG AAGAAACTCG 2640

ACACAGCTAA GATGGAAGAG TACGCAAACC GTGCCCTTAC AGAATGCTCA ACAATGGAAG 2700

AAGTTCTTGA ACTTCAAAAA GAATACGTTA ATTTTGATTA ATCGAAAAGT CCCTGCAACT 2760

CAGTTACAGG GATTTTTTTG ATATTTTAAA AAGAATTTTC AAGAAAATCT TTCTTATAGA 2820

AAGTCCAACC TTGAAAAAGT AGTGGTCAGA ACAAAAAATA CTTAAATGGT TCATAAAATT 2880

CTTGACAAGT TGGATATTTA GGAGTAAACT ATTAACCAGT TAAGTAATAG AGAGGAGTTT 2940

CTGCAATTTA GAAATGAATT GCAACTAGAA ATATCAAATA GAAAGAGAGT TTCGATGAAA 3000

ATTAATAAGA AATACCTTGT TGGTTCTGCG GCACTTTGAT TTTAAGTGTT TGTTCTTACG 3060

AGTTGGGACT GTATCAAGCT AGAACGGTTA AGGAAAATAA TCGTGTTTCC TATATAGATG 3120

GAAAACAAGC GACGCAAAAA ACGGAGAATT TGACTCCTGA TGAGGTTAGC AAGCGTGAAG 3180

GAATCAATGC TGAGCAAATC GTCATCAAGA TAACAGACCA AGGCTATGTC ACTTCACATG 3240

GCGACCACTA TCATTATTAC AATGGTAAGG TTCCTTATGA CGCTATCATC AGTGAAGAAT 3300

TACTCATGAA AGATCCAAAC TATAAGCTAA AAGATGAGGA TATTGTTAAT GAGGTCAAGG 3360

GTGGATATGT TATCAAGGTA GATGGAAAAT ACTATGTTTA CCTTAAGGAT GCTGCCCACG 3420

CGGATAACGT CCGTACAAAA GAGGAAATCA ATCGACAAAA ACAAGAGCAT AGTCAACATC 3480

GTGAAGGTGG AACTCCAAGA AACGATGGTG CTGTTGCCTT GGCACGTTCG CAAGGACGCT 3540

ATACTACAGA TGATGGTTAT ATCTTTAATG CTTCTGATAT CATAGAGGAT ACTGGTGATG 3600

CTTATATCGT TCCTCATGGA GATCATTACC ATTACATTCC TAAGAATGAG TTATCAGCTA 3660

GCGAGTTGGC TGCTGCAGAA GCCTTCCTAT CTGGTCGAGG AAATCTGTCA AATTCAAGAA 3720

CCTATCGCCG ACAAAATAGC GATAACACTT CAAGAACAAA CTGGGTACCT TCTGTAAGCA 3780

ATCCAGGAAC TACAAATACT AACACAAGCA ACAACAGCAA CACTAACAGT CAAGCAAGTC 3840

AAAGTAATGA CATTGATAGT CTCTTGAAAC AGCTCTACAA ACTGCCTTTG AGTCAACGAC 3900

ATGTAGAATC TGATGGCCTT GTCTTTGATC CAGCACAAAT CACAAGTCGA ACAGCTAGAG 3960

GTGTTGCAGT GCCACACGGA GATCATTACC ACTTCATCCC TTACTCTCAA ATGTCTGAAT 4020

TGGAAGAACG AATCGCTCGT ATTATTCCCC TTCGTTATCG TTCAAACCAT TGGGTACCAG 4080

ATTCAAGGCC AGAACAACCA AGTCCACAAC CGACTCCGGA ACCTAGTCCA GGCCCGCAAC 4140

CTGCACCAAA TCTTAAAATA GACTCAAATT CTTCTTTGGT TAGTCAGCTG GTACGAAAAG 4200

TTGGGGAAGG ATATGTATTC GAAGAAAAGG GCATCTCTCG TTATGTCTTT GCGAAAGATT 4260

TACCATCTGA AACTGTTAAA AATCTTGAAA GCAAGTTATC AAAACAAGAG AGTGTTTCAC 4320

ACACTTTAAC TGCTAAAAAA GAAAATGTTG CTCCTCGTGA CCAAGAATTT TATGATAAAG 4380

CATATAATCT GTTAACTGAG GCTCATAAAG CCTTGTTTGA AAATAAGGGT CGTAATTCTG 4440

ATTTCCAAGC CTTAGACAAA TTATTAGAAC GCTTGAATGA TGAATCGACT AATAAAGAAA 4500

AATTGGTAGA TGATTTATTG GCATTCCTAG CACCAATTAC CCATCCAGAG CGACTTGGCA 4560

AACCAAATTC TCAAATTGAG TATACTGAAG ACGAAGTTCG TATTGCTCAA TTAGCTGATA 4620

AGTATACAAC GTCAGATGGT TACATTTTTG ATGAACATGA TATAATCAGT GATGAAGGAG 4680

ATGCATATGT AACGCCTCAT ATGGGCCATA GTCACTGGAT TGGAAAAGAT AGCCTTTCTG 4740

ATAAGGAAAA AGTTGCAGCT CAAGCCTATA CTAAAGAAAA AGGTATCCTA CCTCCATCTC 4800

CAGACGCAGA TGTTAAAGCA AATCCAACTG GAGATAGTGC AGCAGCTATT TACAATCGTG 4860

TGAAAGGGGA AAAACGAATT CCACTCGTTC GACTTCCATA TATGGTTGAG CATACAGTTG 4920

AGGTTAAAAA CGGTAATTTG ATTATTCCTC ATAAGGATCA TTACCATAAT ATTAAATTTG 4980

CTTGGTTTGA TGATCACACA TACAAAGCTC CAAATGGCTA TACCTTGGAA GATTTGTTTG 5040

CGACGATTAA GTACTACGTA GAACACCCTG ACGAACGTCC ACATTCTAAT GATGGATGGG 5100

GCAATGCCAG TGAGCATGTG TTAGGCAAGA AAGACCACAG TGAAGATCCA AATAAGAACT 5160

TCAAAGCGGA TGAAGAGCCA GTAGAGGAAA CACCTGCTGA GCCAGAAGTC CCTCAAGTAG 5220

AGACTGAAAA AGTAGAAGCC CAACTCAAAG AAGCAGAAGT TTTGCTTGCG AAAGTAACGG 5280

ATTCTAGTCT GAAAGCCAAT GCAACAGAAA CTCTAGCTGG TTTACGAAAT AATTTGACTC 5340

TTCAAATTAT GGATAACAAT AGTATCATGG CAGAAGCAGA AAAATTACTT GCGTTGTTAA 5400

AAGGAAGTAA TCCTTCATCT GTAAGTAAGG AAAAAATAAA CTAATGAAAA ATGAAAGTCT 5460

CGATAAAGAG GCTTTCATTT TTATTATGTA TATATGTAAA ATTCTTGACA AGCAATATTA 5520

AAAAGAGTAA ACTATTAACT AGTTAATTAA CCGGTTTATT ACTTTATAGT GAATCAAATA 5580

TACTTAAGAA AAGAGGAAAG AATGAAAATT AATAAAAAAT ATCTAGCAGG TTCAGTGGCA 5640

GTCCTTGCCC TAAGTGTTTG TTCCTATGAA CTTGGTCGTC ACCAAGCTGG TCAGGTTAAG 5700

AAAGAGTCTA ATCGAGTTkC TTATATAGAT GGTGATCAGG CTGGTCAAAA GGCAGAAAAC 5760

TTGACACCAG ATGAAGTCAG TAAGAGGGAG GGGATCAACG CCGAACAAAT CGTCATCAAG 5820

ATTACGGATC AAGGTTATGT GACCTCTCAT GGAGACCATT ATCATTACTA TAATGGCAAG 5880

GTCCCTTATG ATGCCATCAT CAGTGAAGAG CTCCTCATGA AAGATCCGAA TTATCAGTTG 5940

AAGGATTCAG ACATTGTCAA TGAAATCAAG GGTGGTTATG TTATCAAGGT AGATGGAAAA 6000

TACTATGTTT ACCTTAAGGA TGCAGCTCAT GCGGATAATA TTCGGACAAA AGAAGAGATT 6060

AAACGTCAGA AGCAGGAACA CAGTCATAAT CACGGGGGTG GTTCTAACGA TCAAGCAGTA 6120

GTTGCAGCCA GAGCCCAAGG ACGCTATACA ACGGATGATG GTTATATCTT CAATGCATCT 6180

GATATCATTG AGGACACGGG TGATGCTTAT ATCGTTCCTC ACGGCGACCA TTACCATTAC 6240

ATTCCTAAGA ATGAGTTATC AGCTAGCGAG TTAGCTGCTG CAGAAGCCTA TTGGAATGGG 6300

AAGCAGGGAT CTCGTCCTTC TTCAAGTTCT AGTTATAATG CAAATCCAGC TCAACCAAGA 6360

TTGTCAGAGA ACCACAATCT GACTGTCACT CCAACTTATC ATCAAAATCA AGGGGAAAAC 6420

ATTTCAAGCC TTTTACGTGA ATTGTATGCT AAACCCTTAT CAGAACGCCA TGTGGAATCT 6480

GATGGCCTTA TTTTCGACCC AGCGCAAATC ACAAGTCGAA CCGCCAGAGG TGTAGCTGTC 6540

CCTCATGGTA ACCATTACCA CTTTATCCCT TATGAACAAA TGTCTGAATT GGAAAAACGA 6600

ATTGCTCGTA TTATTCCCCT TCGTTATCGT TCAAACCATT GGGTACCAGA TTCAAGACCA 6660

GAACAACCAA GTCCACAATC GACTCCGGAA CCTAGTCCAA GTCCGCAACC TGCACCAAAT 6720

CCTCAACCAG CTCCAAGCAA TCCAATTGAT GAGAAATTGG TCAAAGAAGC TGTTCGAAAA 6780

GTAGGCGATG GTTATGTCTT TGAGGAGAAT GGAGTTTCTC GTTATATCCC AGCCAAGGAT 6840

CTTTCAGCAG AAACAGCAGC AGGCATTGAT AGCAAACTGG CCAAGCAGGA AAGTTTATCT 6900

CATAAGCTAG GAGCTAAGAA AACTGACCTC CCATCTAGTG ATCGAGAATT TTACAATAAG 6960

GCTTATGACT TACTAGCAAG AATTCACCAA GATTTACTTG ATAATAAAGG TCGACAAGTT 7020

GATTTTGAGG CTTTGGATAA CCTGTTGGAA CGACTCAAGG ATGTCyCAAG TGATAAAGTC 7080

AAGTTAGTGG ATGATATTCT TGCCTTCTTA GCTCCGATTC GTCATCCAGA ACGTTTAGGA 7140

AAACCAAATG CGCAAATTAC CTACACTGAT GATGAGATTC AAGTAGCCAA GTTGGCAGGC 7200

AAGTACACAA CAGAAGACGG TTATATCTTT GATCCTCGTG ATATAACCAG TGATGAGGGG 7260

GATGCCTATG TAACTCCACA TATGACCCAT AGCCACTGGA TTAAAAAAGA TAGTTTGTCT 7320

GAAGCTGAGA GAGCGGCAGC CCAGGCTTAT GCTAAAGAGA AAGGTTTGAC CCCTCCTTCG 7380

ACAGACCATC AGGATTCAGG AAATACTGAG GCAAAAGGAG CAGAAGCTAT CTACAACCGC 7440

GTGAAAGCAG CTAAGAAGGT GCCACTTGAT CGTATGCCTT ACAATCTTCA ATATACTGTA 7500

GAAGTCAAAA ACGGTAGTTT AATCATACCT CATTATGACC ATTACCATAA CATCAAATTT 7560

GAGTGGTTTG ACGAAGGCCT TTATGAGGCA CCTAAGGGGT ATACTCTTGA GGATCTTTTG 7620

GCGACTGTCA AGTACTATGT CGAACATCCA AACGAACGTC CGCATTCAGA TAATGGTTTT 7680

GGTAACGCTA GCGACCATGT TCGTAAAAAT AAGGTAGACC AAGACAGTAA ACCTGATGAA 7740

GATAAGGAAC ATGATGAAGT AAGTGAGCCA ACTCACCCTG AATCTGATGA AAAAGAGAAT 7800

CACGCTGGTT TAAATCCTTC AGCAGATAAT CTTTATAAAC CAAGCACTGA TACGGAAGAG 7860

ACAGAGGAAG AAGCTGAAGA TACCACAGAT GAGGCTGAAA TTCCTCAAGT AGAGAATTCT 7920

GTTATTAACG CTAAGATAGC AGATGCGGAG GCCTTGCTAG AAAAAGTAAC AGATCCTAGT 7980

ATTAGACAAA ATGCTATGGA GACATTGACT GGTCTAAAAA GTAGTCTTCT TCTCGGAACG 8040

AAAGATAATA ACACTATTTC AGCAGAAGTA GATAGTCTCT TGGCTTTGTT AAAAGAAAGT 8100

CAACCGGCTC CTATACAGTA GTAAAATGAA TGGAGCATAT TTTATGGAGA AGTAACCTTT 8160

CGTGTTACTT CTCTTTTTTA GAAAAACGTA ACAGA 8195

(2) INFORMATION FOR SEQ ID NO: 95:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2004 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: double
(D) TOPOLOGY: linear

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 95:

TTTACTAAAA GGAAAAAAGA ACTGATTTCT CAGTCCTTCA TTAATCTTAT TCCACACTAA 60

ATAGGTATGG GTAAACAGGT TGTTGACCTT GGTGAATCTC GACTTCAACG TCTTCGAATT 120

CTTCTACGAT TTCTTGAGCG ATTTCATTGG CAAGTTCTTC GCTTCCGTCT TCACCTACAT 180

AGAAGGTTAC GATTTCACTG TCTTCATCCA ACATATGTTT CAAGGTTTCA GTCAATGTTT 240

GGTGCATATC AGGGTTTGAC ACAAGAATTT TTCCATCCAC CATACCTAAA TTATCGTTTT 300

CATGGATTTC TAAGCCATCG ATCGTTGTAT CACGCACGGC TGTTGTGACG CTTCCGCTAA 360

CGACATCGCT AAGAGCAGCT GTCATACGCT CTTGGTTTTC TTCAATGGAC TTGCTTGGAT 420

CAAAGGCAAG AAGACTTGTC ATACCTTGAG GAAGAGTGCG AGCCTCTACC ACTACCGCTG 480

GTTGCTCCAA AACTTCTGCC GCAGATTGAG CTGCCATGAA GATGTTCTTG TTGTTTGGCA 540

AGAAGATGAT GTTACGGGCA TTAACCTGTT CAACAGCCTT GATAAAGTCT TCTGTTGAAG 600

GGTTCATGGT TTGACCGCCT TCGATAACAT AATCCACGCC TTGAGAACAG AAGATATCTG 660

International Application No
PCT/CA 99/01218

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C12N15/31 C12N15/62 C07K14/315 A61K39/09

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C12N C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
WPI Data, PAJ, CAB Data, STRAND

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98 18930 A (HUMAN GENOME SCIENCES INC ;CHOI GIL H (US); HROMOCKYJ ALEX (US); J) 7 May 1998 (1998-05-07) cited in the application SP103; SEQ ID NOs. 181 and 182; page 85, line 14 - line 42; claims 1-21; table I SEQ ID Nos. 65 and 66; ---	1-12
X	WO 98 18931 A (DOUGHERTY BRIAN A ;HUMAN GENOME SCIENCES INC (US); ROSEN CRAIG A () 7 May 1998 (1998-05-07) SEQ ID No.192 claims 1-20 SEQ ID No. 94 --- -/--	1-12

[X] Further documents are listed in the continuation of box C.

[X] Patent family members are listed in annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance
"E" earlier document but published on or after the international filing date
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O" document referring to an oral disclosure, use, exhibition or other means
"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
28 June 2000	24.07.00

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Hornig, H

Form PCT/ISA/210 (second sheet) (July 1992)